A detailed history of Capital Performance Advisors LLP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Capital Performance Advisors LLP holds 1,730 shares of NBIX stock, worth $202,721. This represents 0.08% of its overall portfolio holdings.

Number of Shares
1,730
Previous 144 1101.39%
Holding current value
$202,721
Previous $16,000 1375.0%
% of portfolio
0.08%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 31, 2025

BUY
$111.62 - $139.44 $177,029 - $221,151
1,586 Added 1101.39%
1,730 $236,000
Q3 2024

Nov 01, 2024

BUY
$114.58 - $153.15 $16,499 - $22,053
144 New
144 $16,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.2B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Capital Performance Advisors LLP Portfolio

Follow Capital Performance Advisors LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Performance Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Capital Performance Advisors LLP with notifications on news.